Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | BCL6 | P41182 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30072681 | 1.00 | LRRK2 (0.42) | LRRK2CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL20568819 | 0.79 | BCL6 (0.34) | LRRK2CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15741185 | 0.78 | LRRK2 (0.40) | LRRK2CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL20836128 | 0.78 | CYP11B2 (0.41) | LRRK2CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL2937411 | 0.78 | LRRK2 (0.40) | LRRK2CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1698600 | 0.78 | NTRK1 (0.42) | LRRK2CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15741203 | 0.78 | LRRK2 (0.40) | LRRK2CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL31622333 | 0.78 | LRRK2 (0.40) | LRRK2CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL5802874 | 0.78 | KCNMA1 (0.40) | LRRK2CYP3A4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL677194 | 0.78 | L3MBTL1 (0.45) | CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4729127-A2 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042776-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-12486285-B2 | BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-12-02 | — | — | US | disclosed |
| US-20250163076-A1 | SYNTHESIS OF BRUTON'S TYROSINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-22 | — | — | US | disclosed |
| US-20250127906-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | UNIVERSITY OF SOUTH CAROLINA | 2025-04-24 | — | — | US | disclosed |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-02-20 | — | — | US | disclosed |
| WO-2025007863-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-09 | — | — | WO | disclosed |
| US-6197964-B1 | CHLORINATION USING BASIC CATALYST; DESALTING, HYDROLYSIS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-06 | — | — | US | disclosed |
| US-6046207-A | FOR INHIBITING ALPHA-1 ADRENORECEPTORS AND TREATING BENIGN PROSTATIC HYPERPLASIA, ALSO CALLED BENIGN PROSTATIC HYPERTROPHY, OR OTHER UROLOGICAL OR GYNECOLOGICAL DISEASES SUCH AS BLADDER OUTLET OBSTRUCTION, NEUROGENIC BLADDER | ABBOTT LABORATORIES | 2000-04-04 | — | — | US | disclosed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | disclosed |
| EP-0942911-A1 | BENZOPYRANOPYRROLE AND BENZOPYRANOPYRIDINE ALPHA-1 ADRENERGIC COMPOUNDS | Abbott Laboratories (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5891882-A | TREATING BENIGN PROSTATIC HYPERPLASIA OR OTHER UROLOGICAL DISEASES SUCH AS BLADDER OUTLET OBSTRUCTION AND NEUROGENIC BLADDER, OR GYNECOLOGICAL SYNDROMES SUCH AS DYSMENORRHEA | ABBOTT LABORATORIES (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1998024791-A1 | BENZOPYRANOPYRROLE AND BENZOPYRANOPYRIDINE ALPHA-1 ADRENERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1998-06-11 | — | — | WO | disclosed |
| US-5710157-A | INSECTICIDES FOR AGRICULTURE | FMC CORPORATION (US) | 1998-01-20 | — | — | US | disclosed |
| US-5593998-A | 2,4-diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides | FMC CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| US-5547954-A | MIXED WITH AGRICULTURAL ACCEPTABLE CARRIER | FMC CORPORATION (US) | 1996-08-20 | — | — | US | disclosed |
| US-5532370-A | FOR INSECTS INCLUDING LARVAE SUCH AS TOBACCO BUDWORM | FMC CORPORATION (US) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | RYR2, CACNA1C, CAMK4 | LRRK2 1697/4885CYP3A4 2634/4885CYP1A2 1551/4885 |
| US-20250127906-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | CDK8, CDK9, CDK18 | LRRK2 980/4885CYP3A4 3460/4885CYP1A2 4043/4885 |
| US-20250163076-A1 | SYNTHESIS OF BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, LYN | LRRK2 291/4885CYP3A4 3534/4885CYP1A2 2799/4885 |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | LRRK2 21/4885CYP3A4 1314/4885CYP1A2 1645/4885 |
| US-12486285-B2 | BCL6 inhibitors | BCL6, BCL6B, BCL3 | LRRK2 1478/4885CYP3A4 3422/4885CYP1A2 3289/4885 |
| US-20260042776-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL9 | LRRK2 1049/4885CYP3A4 3867/4885CYP1A2 3720/4885 |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | LRRK2 31/4885CYP3A4 1822/4885CYP1A2 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.